Drugs / Pembrolizumab/Favezelimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04895722 | Jun 2021 → May 2025 overdue | colorectal cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab/Favezelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895722 ↗ |
| Route | Intravenous | “Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion” NCT04895722 ↗ |